430 related articles for article (PubMed ID: 30021373)
1. Clofazimine: A useful antibiotic for drug-resistant tuberculosis.
Mirnejad R; Asadi A; Khoshnood S; Mirzaei H; Heidary M; Fattorini L; Ghodousi A; Darban-Sarokhalil D
Biomed Pharmacother; 2018 Sep; 105():1353-1359. PubMed ID: 30021373
[TBL] [Abstract][Full Text] [Related]
2. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis.
Gopal M; Padayatchi N; Metcalfe JZ; O'Donnell MR
Int J Tuberc Lung Dis; 2013 Aug; 17(8):1001-7. PubMed ID: 23541151
[TBL] [Abstract][Full Text] [Related]
3.
Xu J; Wang B; Fu L; Zhu H; Guo S; Huang H; Yin D; Zhang Y; Lu Y
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30782992
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline.
Cholo MC; Mothiba MT; Fourie B; Anderson R
J Antimicrob Chemother; 2017 Feb; 72(2):338-353. PubMed ID: 27798208
[TBL] [Abstract][Full Text] [Related]
5. Synergistic activities of clofazimine with moxifloxacin or capreomycin against Mycobacterium tuberculosis in China.
Li G; Xu Z; Jiang Y; Liu H; Zhao LL; Li M; Xu D; Zhao X; Liu Z; Wang R; Wan K
Int J Antimicrob Agents; 2019 Nov; 54(5):642-646. PubMed ID: 31200023
[TBL] [Abstract][Full Text] [Related]
6. Elucidating the role of clofazimine for the treatment of tuberculosis.
O'Donnell MR; Padayatchi N; Metcalfe JZ
Int J Tuberc Lung Dis; 2016 Dec; 20(12):52-57. PubMed ID: 28240574
[TBL] [Abstract][Full Text] [Related]
7. [A study on the activity of clofazimine with antituberculous drugs against Mycobacterium tuberculosis].
Lu Y; Wang B; Zhao WJ; Zheng MQ; Li P; Fu L; Liang BW
Zhonghua Jie He He Hu Xi Za Zhi; 2010 Sep; 33(9):675-8. PubMed ID: 21092635
[TBL] [Abstract][Full Text] [Related]
8. Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis.
Liu Y; Gao J; Du J; Shu W; Wang L; Wang Y; Xue Z; Li L; Xu S; Pang Y
Int J Infect Dis; 2021 Jan; 102():392-396. PubMed ID: 33130209
[TBL] [Abstract][Full Text] [Related]
9. Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis.
Zhang D; Lu Y; Liu K; Liu B; Wang J; Zhang G; Zhang H; Liu Y; Wang B; Zheng M; Fu L; Hou Y; Gong N; Lv Y; Li C; Cooper CB; Upton AM; Yin D; Ma Z; Huang H
J Med Chem; 2012 Oct; 55(19):8409-17. PubMed ID: 22931472
[TBL] [Abstract][Full Text] [Related]
10. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China.
Tang S; Yao L; Hao X; Liu Y; Zeng L; Liu G; Li M; Li F; Wu M; Zhu Y; Sun H; Gu J; Wang X; Zhang Z
Clin Infect Dis; 2015 May; 60(9):1361-7. PubMed ID: 25605283
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis.
Dey T; Brigden G; Cox H; Shubber Z; Cooke G; Ford N
J Antimicrob Chemother; 2013 Feb; 68(2):284-93. PubMed ID: 23054996
[TBL] [Abstract][Full Text] [Related]
12. Clofazimine: current status and future prospects.
Cholo MC; Steel HC; Fourie PB; Germishuizen WA; Anderson R
J Antimicrob Chemother; 2012 Feb; 67(2):290-8. PubMed ID: 22020137
[TBL] [Abstract][Full Text] [Related]
13. Sub-MIC levels of bedaquiline and clofazimine can select
Villellas C; Stevenaert F; Remmerie B; Andries K
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0127523. PubMed ID: 38470194
[TBL] [Abstract][Full Text] [Related]
14. Bedaquiline- and clofazimine- selected Mycobacterium tuberculosis mutants: further insights on resistance driven largely by Rv0678.
Snobre J; Villellas MC; Coeck N; Mulders W; Tzfadia O; de Jong BC; Andries K; Rigouts L
Sci Rep; 2023 Jun; 13(1):10444. PubMed ID: 37369740
[TBL] [Abstract][Full Text] [Related]
15. Clofazimine protects against Mycobacterium tuberculosis dissemination in the central nervous system following aerosol challenge in a murine model.
Baijnath S; Moodley C; Ngcobo B; Singh SD; Kruger HG; Arvidsson PI; Naicker T; Pym A; Govender T
Int J Antimicrob Agents; 2018 Jan; 51(1):77-81. PubMed ID: 28843822
[TBL] [Abstract][Full Text] [Related]
16. Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies.
Hwang TJ; Dotsenko S; Jafarov A; Weyer K; Falzon D; Lunte K; Nunn P; Jaramillo E; Keshavjee S; Wares DF
BMJ Open; 2014 Jan; 4(1):e004143. PubMed ID: 24384902
[TBL] [Abstract][Full Text] [Related]
17. Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis.
Xu J; Wang B; Hu M; Huo F; Guo S; Jing W; Nuermberger E; Lu Y
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320727
[TBL] [Abstract][Full Text] [Related]
18. Dose-related adverse events in South African patients prescribed clofazimine for drug-resistant tuberculosis.
Misra N; Padayatchi N; Naidoo P
S Afr Med J; 2019 Dec; 110(1):32-37. PubMed ID: 31865940
[TBL] [Abstract][Full Text] [Related]
19. Clofazimine: an old drug for never-ending diseases.
Riccardi N; Giacomelli A; Canetti D; Comelli A; Intini E; Gaiera G; Diaw MM; Udwadia Z; Besozzi G; Codecasa L; Biagio AD
Future Microbiol; 2020 May; 15():557-566. PubMed ID: 32476494
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the effect of clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid.
Kim S; Louie A; Drusano GL; Almoslem M; Kim S; Myrick J; Nole J; Duncanson B; Peloquin CA; Scanga CA; Yamada W; Neely M; Schmidt S
Int J Antimicrob Agents; 2022 Feb; 59(2):106509. PubMed ID: 34958863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
